Palliative chemotherapy in head and neck squamous cell cancer-What is best in Indian population? A time without symptoms, treatment toxicity score based study

Indian Journal of Medical and Paediatric Oncology

Volumn 34, Issue 1, 2013, Pages 11-15

  Anuradha, V ^a   Anand, B B ^b   Suresh, A V S ^c   Sinha, Sudha ^c   Chinna Babu, S ^d   Suresh, K ^d  

^a OSMANIA MEDICAL COLLEGE   (India)

^b KMIO   (India)

^c MNJ Institute of Oncology   (India)

^d ClinSync Clinical Research Pvt Ltd   (India)

Author keywords

Head and neck cancer; India; quality of life; time without symptoms treatment toxicity

Indexed keywords

CISPLATIN; FLUOROURACIL; GEFITINIB; METHOTREXATE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOSPITALIZATION; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84879741292     PISSN: 09715851     EISSN: 09752129     Source Type: Journal    
DOI: 10.4103/0971-5851.113404     Document Type: Article

References (14)

1. IARC. GLOBOCAN, 2002. Available from: http://www. depdb.iarc.fr/globocan. [Last accessed on 2012 Jan 23] 2. Hotte SJ, Wright JR. Understanding the results of meta-analyses in the treatment of head and neck squamous cell cancer. Hematol Oncol Clin North Am 2008;22:1257-66.
2. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21:vii 252-61.
3. Rao RR, Konnpal A, Lalit B, Amit D, Sameer K, Shneh R, et al. Survival benefit and efficacy of gefitinib in recurrent metastatic head and neck cancer. Indian J Med Paediatr Oncol 2007:28:5-10.
4. Grandis JR, Tweardy D J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84. (Pubitemid 23229640)
5. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7. (Pubitemid 46606387)
6. Wheeler R H, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol 2005;23:507s.
7. Kirby AM, A'Hern RP, D'Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006;94:631-6. (Pubitemid 43361892)
8. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37. (Pubitemid 41540110)
9. Vermorken B, Bourhis J, Trigo J, Kies M, Leon X, Mueser M, et al. Baselga Cetuximab (Erbitux®) in recurrent/metastatic (R and M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. Proc Am Soc Clin Oncol 2005;23:501.
10. NCCN guidelines for treatment of head and neck squamous cell carcinoma, 2012 Available from: http://www.nccn.org/about/news/newsinfo.asp?NewsID=110. [Last accessed on 2012 Dec 06]
11. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: Implications for diagnostic radiologists. Br J Radiol 2001;74:983-6.
12. Common toxicity criteria, 2009 Available from: http://www.ctep.cancer. gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf.[Last accessed on 2012 Dec 06]
13. Attili SV. Role and impact of "non-conventional/alternative medicines" on quality of life as well as disease free and overall survival in patients with locally advanced and metastatic lung cancer. J Thorac Oncol 2008;3:1-42.
14. Stewart JS, Cohen EE, Licitra L, Van Herpen C M, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864-71.